{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-048961","form_type":"8-K","ticker":"SRPT","cik":"0000873303","company_name":"Sarepta Therapeutics, Inc.","filed_at":"2021-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.012595+00:00","generated_at":"2026-06-29T01:24:55.178865+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sarepta to initiate pivotal Part B of MOMENTUM study for SRP-5051 in DMD patients","bullets":["Positive FDA interactions enable early start of Part B of MOMENTUM study for SRP-5051.","Part B expected to serve as pivotal study seeking accelerated approval for exon 51 skipping DMD patients.","Study will enroll 20-40 patients, ages 7-21, both ambulatory and non-ambulatory.","Company anticipates initiating Part B in Q4 2021; protocol submission next week.","SRP-5051 is a next-generation PPMO therapy; prior Part A data suggested efficacy."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-048961","json":"https://secwatch.observer/filing/0001564590-21-048961.json","markdown":"https://secwatch.observer/filing/0001564590-21-048961.md","text":"https://secwatch.observer/filing/0001564590-21-048961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/0001564590-21-048961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/873303/000156459021048961/srpt-8k_20210927.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:24:55.178865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}